Boston battens down the hatches for possible stent storm
This article was originally published in Clinica
Executive Summary
Boston Scientific CEO James Tobin reported profits that fell by 22% before special charges in the first quarter and warned that, with the likelihood of a further loss of market share in stents for the rest of the year, the company had to "batten down the hatches" to reduce expenditure.